Angiotensin II suppression in SARS-CoV-2 infection : a therapeutic approach
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
---|---|
Enthalten in: |
Nefrologia - 40(2020), 3 vom: 25. Mai, Seite 213-216 |
Sprache: |
Englisch |
---|
Weiterer Titel: |
Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica |
---|
Beteiligte Personen: |
Lamas-Barreiro, José María [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 01.07.2020 Date Revised 03.11.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.nefro.2020.04.006 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM310389712 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM310389712 | ||
003 | DE-627 | ||
005 | 20231225140003.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.nefro.2020.04.006 |2 doi | |
028 | 5 | 2 | |a pubmed24n1034.xml |
035 | |a (DE-627)NLM310389712 | ||
035 | |a (NLM)32456945 | ||
035 | |a (PII)S0211-6995(20)30044-8 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lamas-Barreiro, José María |e verfasserin |4 aut | |
245 | 1 | 0 | |a Angiotensin II suppression in SARS-CoV-2 infection |b a therapeutic approach |
246 | 3 | 3 | |a Supresión de angiotensina II en la infección por el virus SARS-CoV-2: una propuesta terapéutica |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.07.2020 | ||
500 | |a Date Revised 03.11.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
650 | 7 | |a Lisinopril |2 NLM | |
650 | 7 | |a E7199S1YWR |2 NLM | |
650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
650 | 7 | |a EC 3.4.15.1 |2 NLM | |
650 | 7 | |a ACE2 protein, human |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
650 | 7 | |a Ace2 protein, mouse |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
650 | 7 | |a Ace2 protein, rat |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
650 | 7 | |a EC 3.4.17.23 |2 NLM | |
650 | 7 | |a Losartan |2 NLM | |
650 | 7 | |a JMS50MPO89 |2 NLM | |
700 | 1 | |a Alonso-Suárez, Mario |e verfasserin |4 aut | |
700 | 1 | |a Fernández-Martín, Jorge Julián |e verfasserin |4 aut | |
700 | 1 | |a Saavedra-Alonso, Jesus Angel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nefrologia |d 2018 |g 40(2020), 3 vom: 25. Mai, Seite 213-216 |w (DE-627)NLM270991409 |x 2013-2514 |7 nnns |
773 | 1 | 8 | |g volume:40 |g year:2020 |g number:3 |g day:25 |g month:05 |g pages:213-216 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nefro.2020.04.006 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 40 |j 2020 |e 3 |b 25 |c 05 |h 213-216 |